Capricor Therapeutics (CAPR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$98.6 million.
- Capricor Therapeutics' Enterprise Value fell 1592.09% to -$98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.6 million, marking a year-over-year decrease of 1592.09%. This contributed to the annual value of -$151.5 million for FY2024, which is 28370.4% down from last year.
- As of Q3 2025, Capricor Therapeutics' Enterprise Value stood at -$98.6 million, which was down 1592.09% from -$122.8 million recorded in Q2 2025.
- Capricor Therapeutics' Enterprise Value's 5-year high stood at -$28.5 million during Q3 2023, with a 5-year trough of -$151.5 million in Q4 2024.
- Its 5-year average for Enterprise Value is -$61.9 million, with a median of -$41.9 million in 2021.
- As far as peak fluctuations go, Capricor Therapeutics' Enterprise Value skyrocketed by 3881.29% in 2023, and later tumbled by 31681.0% in 2025.
- Over the past 5 years, Capricor Therapeutics' Enterprise Value (Quarter) stood at -$34.9 million in 2021, then fell by 18.74% to -$41.4 million in 2022, then rose by 4.67% to -$39.5 million in 2023, then plummeted by 283.7% to -$151.5 million in 2024, then soared by 34.95% to -$98.6 million in 2025.
- Its Enterprise Value was -$98.6 million in Q3 2025, compared to -$122.8 million in Q2 2025 and -$144.8 million in Q1 2025.